S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
BREAKING: Tiny biotech successfully treats blindness (Ad)
CarMax Slides On Earnings Disappointment, Time To Celebrate?
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
BREAKING: Tiny biotech successfully treats blindness (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
BREAKING: Tiny biotech successfully treats blindness (Ad)
CarMax Slides On Earnings Disappointment, Time To Celebrate?
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
BREAKING: Tiny biotech successfully treats blindness (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
BREAKING: Tiny biotech successfully treats blindness (Ad)
CarMax Slides On Earnings Disappointment, Time To Celebrate?
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
BREAKING: Tiny biotech successfully treats blindness (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
BREAKING: Tiny biotech successfully treats blindness (Ad)
CarMax Slides On Earnings Disappointment, Time To Celebrate?
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
BREAKING: Tiny biotech successfully treats blindness (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
NASDAQ:ANIP

ANI Pharmaceuticals (ANIP) Competitors

$58.06
-0.83 (-1.41%)
(As of 09/29/2023 ET)
Compare
Today's Range
$57.95
▼
$59.28
50-Day Range
$50.78
▼
$64.61
52-Week Range
$31.21
▼
$65.89
Volume
149,379 shs
Average Volume
157,370 shs
Market Capitalization
$1.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

ANIP vs. VKTX, ETNB, AUPH, BHVN, KNSA, OPK, MIRM, XNCR, MRUS, and GERN

Should you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include Viking Therapeutics (VKTX), 89bio (ETNB), Aurinia Pharmaceuticals (AUPH), Biohaven (BHVN), Kiniksa Pharmaceuticals (KNSA), OPKO Health (OPK), Mirum Pharmaceuticals (MIRM), Xencor (XNCR), Merus (MRUS), and Geron (GERN). These companies are all part of the "pharmaceutical preparations" industry.

ANI Pharmaceuticals vs.

Viking Therapeutics (NASDAQ:VKTX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations.

Viking Therapeutics presently has a consensus price target of $30.25, indicating a potential upside of 173.26%. ANI Pharmaceuticals has a consensus price target of $71.67, indicating a potential upside of 23.44%. Given ANI Pharmaceuticals' higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than ANI Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viking Therapeutics
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00
ANI Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Viking Therapeutics received 162 more outperform votes than ANI Pharmaceuticals when rated by MarketBeat users. Likewise, 79.75% of users gave Viking Therapeutics an outperform vote while only 64.25% of users gave ANI Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Viking TherapeuticsOutperform Votes
579
79.75%
Underperform Votes
147
20.25%
ANI PharmaceuticalsOutperform Votes
417
64.25%
Underperform Votes
232
35.75%

In the previous week, ANI Pharmaceuticals had 2 more articles in the media than Viking Therapeutics. MarketBeat recorded 4 mentions for ANI Pharmaceuticals and 2 mentions for Viking Therapeutics. ANI Pharmaceuticals' average media sentiment score of 0.95 beat Viking Therapeutics' score of 0.90 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viking Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ANI Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Viking Therapeutics has a net margin of 0.00% compared to Viking Therapeutics' net margin of -1.29%. Viking Therapeutics' return on equity of 15.77% beat ANI Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Viking TherapeuticsN/A -36.28% -33.42%
ANI Pharmaceuticals -1.29%15.77%6.81%

ANI Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A-$68.87M-$0.91-12.16
ANI Pharmaceuticals$316.39M3.72-$47.90M-$0.48-120.96

78.1% of Viking Therapeutics shares are held by institutional investors. Comparatively, 69.8% of ANI Pharmaceuticals shares are held by institutional investors. 4.4% of Viking Therapeutics shares are held by company insiders. Comparatively, 28.5% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Viking Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.

Summary

Viking Therapeutics and ANI Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.


Get ANI Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANIP vs. The Competition

Export to Excel
MetricANI PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.19B$5.74B$4.44B$6.31B
Dividend YieldN/A2.74%2.55%7.64%
P/E Ratio-120.963.0589.0210.45
Price / Sales3.72143.512,987.2955.17
Price / Cash14.5922.7693.24103.06
Price / Book3.243.723.774.67
Net Income-$47.90M$198.67M$122.85M$186.41M
7 Day Performance-0.79%0.79%0.41%-0.08%
1 Month Performance-10.14%-8.88%-4.58%-6.49%
1 Year Performance80.65%4.43%9.85%6.20%

ANI Pharmaceuticals Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VKTX
Viking Therapeutics
2.0591 of 5 stars		$11.93
+2.2%		$30.25
+153.7%		+302.5%$1.19BN/A-13.1022Positive News
ETNB
89bio
1.9481 of 5 stars		$15.68
+3.0%		$37.44
+138.8%		+182.8%$1.18BN/A-7.4345Short Interest ↓
AUPH
Aurinia Pharmaceuticals
1.5902 of 5 stars		$8.17
+0.7%		$13.33
+63.2%		+4.3%$1.17B$134.03M-16.34300Short Interest ↑
Positive News
BHVN
Biohaven
1.6636 of 5 stars		$17.65
+2.4%		$25.25
+43.1%		-82.8%$1.21B$462.51M-2.38928
KNSA
Kiniksa Pharmaceuticals
2.1472 of 5 stars		$16.68
+2.1%		$20.00
+19.9%		+45.2%$1.17B$220.18M5.10220
OPK
OPKO Health
2.3554 of 5 stars		$1.57
-1.9%		$3.85
+145.2%		-14.4%$1.21B$1.00B-5.814,196News Coverage
Gap Up
MIRM
Mirum Pharmaceuticals
2.4579 of 5 stars		$30.38
-1.9%		$53.33
+75.6%		+50.5%$1.16B$77.06M-6.40213Positive News
XNCR
Xencor
1.8361 of 5 stars		$20.08
-0.3%		$44.20
+120.1%		-21.0%$1.22B$164.58M-9.38281
MRUS
Merus
2.1864 of 5 stars		$22.77
+0.8%		$44.33
+94.7%		+19.1%$1.14B$41.59M-5.90164News Coverage
Positive News
GERN
Geron
2.0098 of 5 stars		$2.16
-0.5%		$4.75
+119.9%		-8.2%$1.13B$600,000.00-6.00107Short Interest ↑
News Coverage

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:ANIP) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -